Bevacizumab Injection [Avastin]

DRUG5 trials

Conditions

Colorectal CancerDiabetic MaculopathyDiabetic RetinopathyMacular EdemaProliferative Diabetic RetinopathyRetinal NeovascularizationTractional Retinal DetachmentVitreous Hemorrhage

Phase 3

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

NCT03950154

Tianjin Medical University Cancer Institute and HospitalColorectal Cancer

Start: 2019-06-01End: 2023-08-01Target: 198Updated: 2023-08-01

Phase 4

Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema

NCT03211741

University Hospital, GhentMacular Edema, Retinal Neovascularization

Start: 2013-11-22End: 2024-12-31Target: 500Updated: 2023-12-08

Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

NCT05514925

Khairallah MoncefProliferative Diabetic Retinopathy, Tractional Retinal Detachment, Vitreous Hemorrhage

Start: 2017-11-21End: 2022-12-31Target: 60Updated: 2022-08-31

Aflibercept and Bevacizumab for Diabetic Maculopathies

RecruitingNCT06850571

Al-Mustansiriyah UniversityDiabetic Maculopathy

Start: 2025-02-20End: 2025-12-01Target: 102Updated: 2025-09-19

Unknown Phase

IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes

CompletedNCT06559488

Universitas PadjadjaranDiabetic Retinopathy, Vitreous Hemorrhage

Start: 2018-04-02End: 2019-03-31Updated: 2024-08-27

Related Papers

Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing

Frontiers in Oncology2025-06-091 citations

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.